Prognostic Value of CD133 and SOX2 in Advanced Cancer

Figure 6

Trial sequential analysis (TSA) for cancer-specific survival (CSS) and overall survival (OS) of CD133 positive expression (α = 5%, β = 10%, and the relative risk reduction (RRR) = 20%).